<DOC>
	<DOCNO>NCT00280397</DOCNO>
	<brief_summary>The purpose study determine maximum tolerable dose ( MTD ) relate effect E7080 administer patient solid tumor resistant approve exist anti-tumor therapy , appropriate treatment available .</brief_summary>
	<brief_title>An Open Label Phase I Dose Escalation Study E7080 Administered Patients With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Lenvatinib</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients histologically and/or cytologically confirm solid tumor require treatment . 2 . Patients solid tumor resistant approve conventional antitumor therapy , appropriate treatment available . 3 . Patients complete previous treatment ( include surgery radiotherapy ) supportive care ( transfusion blood , blood component granulocyte colonystimulating factor [ GCSF ] treatment ) least 4 week registration , sign symptom acute toxicity occur previous treatment . 4 . Patients 20 year old less 75 year age time registration . 5 . Patients 0 1 Performance Status ( PS ) establish Eastern Cooperative Oncology Group ( ECOG . ) 6 . Patients stay hospital 1 cycle treatment . 7 . Patients expect survive 3 month start study drug administration . 8 . Patients provide write informed consent participation study . Exclusion criterion : 1 . Patients clinical symptom due brain metastasis require treatment . 2 . Patients follow laboratory test finding : 1 . Hemoglobin le 9.0 g/dL 2 . Neutrophil count le 1.5 x 10 9/L 3 . Platelet count le 100 x 10 9/L 4 . Serum bilirubin great 1.5 mg/dL 5 . AST , ALT great 100 IU/L 6 . Serum creatinine great 1.5 mg/dL creatinine clearance le 50 mL/minute 3 . Patients positive reaction human immunodeficiency virus ( HIV ) hepatitis virus C ( HCV ) antibody hepatitis B virus surface ( HBs ) antigen , patient untreated serious infection . 4 . Patients clinically significant cardiac disorder unstable ischemic heart diseases include myocardial infarction within six month registration study . 5 . Patients mark Baseline prolongation QT/QTc interval ( QTc interval great 450 msec male great 470 msec female ) use Fridericia method QTc analysis . 6 . Patients hemorrhagic thrombotic disease use therapeutic dos anticoagulant aspirin , warfarin , ticlopidine . 7 . Patients diagnosed hypertension ( define repeatedly measure blood pressure = 160/90 mmHg ) Screening , irrespective use antihypertensive drug . 8 . Patients proteinuria great 1 bedside test . 9 . Patients history insufficient gastrointestinal absorption , patient receive gastric intestinal anastomosis within 4 week registration . 10 . Patients history alcoholism , drug addiction mental physical disorder , , investigator opinion , may impair study compliance . 11 . Patients receive investigational drug within 30 day registration study . 12 . Patients receive CYP3A4 inhibitor include itraconazole , erythromycin , clarithromycin , diltiazem verapamil screen use drug study . 13 . Pregnant nursing patient ( female patient pregnancy potential must negative pregnancy test perform registration , postmenopausal woman must amenorrheic least 12 month . ) Female patient must use appropriate contraception . 14 . Fertile male patient refuse use contraception , whose female partner use appropriate contraception . 15 . Patients judge investigator inappropriate study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Cancer , solid tumor</keyword>
</DOC>